Ultragenyx Pharmaceutical | RARE - Cash And Equivalent


Ultragenyx Pharmaceutical reported $202.51M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 819.69M 27.33M Dec/2025
Agios Pharmaceuticals USD 89.13M 3.58M Dec/2025
Alnylam Pharmaceuticals USD 1.66B 167M Dec/2025
BioCryst Pharmaceuticals USD 335.91M 251.83M Dec/2025
BioMarin Pharmaceutical USD 1.31B 61.57M Dec/2025
Esperion Therapeutics USD 92.45M 6.39M Sep/2025
Immunic USD 15.48M 19.65M Dec/2025
Insmed USD 510.44M 175.68M Dec/2025
Ionis Pharmaceuticals USD 2.68B 437M Dec/2025
Karyopharm Therapeutics USD 60.54M 22.87M Dec/2025
Kyowa Hakko Kirin JPY 234.6B 20.23B Jun/2025
MacroGenics USD 57.22M 22.91M Dec/2025
Moderna USD 2.6B 1.46B Dec/2025
Neurocrine Biosciences USD 713M 372.8M Dec/2025
PTC Therapeutics USD 984.65M 312.03M Dec/2025
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Sarepta Therapeutics USD 801.28M 188.2M Dec/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
Vertex Pharmaceuticals USD 6.61B 321.1M Dec/2025
Xoma USD 143.9M 7.68M Jun/2024